ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2473

Criterion Validity of Modified Rodnan Skin Score: Does It Capture Skin Thickness or Hardening? Results of a Large Skin Histology Study

Shervin Assassi1, Ruhani Desai2, Jeffrey Browning3, Samuel Theodore1, Meng Zhang1, Brian Skaug1, Jerry Alonso1, Zsuzsanna McMahan1, Maureen Mayes1 and Minghua Wu1, 1UTHealth Houston Division of Rheumatology, Houston, TX, 2UTHealth Houston Division of Rheumatology, DeLand, FL, 3Boston University, Cambridge, MA

Meeting: ACR Convergence 2024

Keywords: Fibroblasts, Dermal, Scleroderma, Systemic, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Modified Rodnan Skin Score is a widely used outcome measure for skin involvement in systemic sclerosis (SSc). Its criterion validity (comparison to the gold standard) was originally established by Dr. Rodnan by comparing the clinical skin scoring with the weight of punch skin biopsy performed on the dorsal surface of the forearm in patients with diffuse cutaneous involvement. A comparison to the histological evaluation of punch skin biopsies was not performed. Moreover, the words “skin thickening” and “skin induration” (hardening) are used interchangeably when referring to the construct captured by mRSS. However, dermal thickness and hardening (also influenced by extracellular matrix density) are non-overlapping constructs. Lastly, mRSS is used to evaluate skin involvement in limited and diffuse cutaneous subsets in routine clinical care, although the criterion validity of mRSS in the limited cutaneous subset has not yet been established. Herein, we investigated the correlation of clinical local skin scoring and total mRSS with histological measures in forearm skin biopsies of SSc patients.

Methods: 55 SSc patients were included, consisting of 39 with a diffuse subtype (including 13 with early disease [disease duration < 3 years]) and 16 with limited cutaneous involvement (including 6 with early disease). All clinical skin scorings were performed by one experienced SSc expert. A 3-mm punch skin biopsy was taken from the dorsal surface of the forearm. Special attention was given to performing a full-thickness skin biopsy with the inclusion of the fat layer. Histological evaluation was performed in a blinded fashion. It included measurement of dermal thickness on H&E staining (from dermo-epidermal junction to the beginning of subcutaneous fat layer), automated assessment of collagen density in the dermis on Masson trichrome staining using Image J, and a semi-quantitative assessment of skin fibrosis by an SSc skin pathology expert (ranging from 0 [normal] to 3 [severely fibrotic]).

Results: The clinical local skin score at the biopsy site highly correlated with the overall mRSS (Rs=0.85, p< 0.001). As shown in Table 1, it also correlated significantly with histological collagen density and semi-quantitative fibrosis score but not with histological dermal thickness. Similarly, total mRSS showed stronger correlations with collagen density and fibrosis scoring than with histological dermal thickness.   

Tables 2 and 3 show the correlation of local clinical score/total mRSS with skin histology measures in diffuse and limited subtypes, respectively.  Consistent with the aforementioned results, the local skin score and total mRSS did not correlate significantly with the histological dermal thickness in diffuse or limited subsets, while they correlated with the collagen density in both clinical subsets.

Conclusion: Local skin score and mRSS show moderate criterion validity with histological collagen density but poorer correlation with histological dermal thickness in the overall SSc group and its diffuse and limited subsets. True to the literal meaning of the word scleroderma (scleros=hard and derma=skin), mRSS assessment method reflects better skin induration (hardening) than skin thickening.

Supporting image 1

Table 1: Correlation of clinical skin scoring with histology among all SSc patients

Supporting image 2

Table 2: Correlation of clinical skin scoring with histology among patients with diffuse skin involvement

Supporting image 3

Table 3: Correlations of clinical skin scoring with histology among patients with limited skin involvement


Disclosures: S. Assassi: AstraZeneca, 2, aTyr, 2, 5, BMS, 2, Boehringer-Ingelheim, 2, 5, CSL Behring, 2, Janssen, 5, Merck/MSD, 2, TeneoFour, 2; R. Desai: None; J. Browning: None; S. Theodore: None; M. Zhang: None; B. Skaug: None; J. Alonso: None; Z. McMahan: Boehringer-Ingelheim, 2; M. Mayes: AstraZeneca, 5, Atyr, 5, Boehringer-Ingelheim, 1, 5, Horizon Therapeutics, 5, Merck/MSD, 5; M. Wu: Bristol-Myers Squibb(BMS), 5, CSL Behring, 5.

To cite this abstract in AMA style:

Assassi S, Desai R, Browning J, Theodore S, Zhang M, Skaug B, Alonso J, McMahan Z, Mayes M, Wu M. Criterion Validity of Modified Rodnan Skin Score: Does It Capture Skin Thickness or Hardening? Results of a Large Skin Histology Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/criterion-validity-of-modified-rodnan-skin-score-does-it-capture-skin-thickness-or-hardening-results-of-a-large-skin-histology-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/criterion-validity-of-modified-rodnan-skin-score-does-it-capture-skin-thickness-or-hardening-results-of-a-large-skin-histology-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology